Location History:
- Temecula, CA (US) (2006 - 2018)
- Temecula, CA (2020)
Company Filing History:
10 out of 23 
7 out of 23 
7 out of 4,770 
Years Active: 2006-2020
Title: Innovator Spotlight: Jeffrey Roger Roppe and his Contributions to Ophthalmology
Introduction:
In the world of innovations and patents, there are exceptional individuals who dedicate their careers to advancing scientific research and improving the lives of many. One such individual is Jeffrey Roger Roppe, a highly accomplished inventor from Temecula, CA. With an impressive record of 29 patents to his name, Roppe's contributions have made a significant impact on the field of ophthalmology, specifically in the prevention and treatment of age-related macular degeneration (AMD) and related eye diseases.
Overview of Roppe's Latest Patents:
Among his influential patents, Roppe's recent inventions focus on aliphatic prolinamide derivatives and radioligands for imaging the LPA-1 receptor.
1. Aliphatic prolinamide derivatives: Roppe's invention entails novel aliphatic prolinamide derivatives of Formula I, which includes their pharmaceutically acceptable salts, prodrugs, and other related compounds. These derivatives have shown promise in preventing and treating various eye diseases, including dry-AMD, wet-AMD, geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells. By inhibiting the HTRA1 protein, the compounds offer potential therapeutic benefits for numerous diseases mediated by HTRA1.
2. Radioligands for imaging the LPA-1 receptor: Roppe's second invention relates to radiolabeled LPA1 receptor antagonists. These compounds, or their pharmaceutically acceptable salts, enable quantitative imaging of LPA1 receptors in mammals. This innovation holds promise for enhancing our understanding of LPA1 receptor activity and exploring potential diagnostic and therapeutic avenues.
Contributions to Companies and Collaborators:
Throughout his career, Roppe has made significant contributions to notable companies and has collaborated with renowned colleagues. Some of the companies he has worked with include Amira Pharmaceuticals, Inc. and Panmira Pharmaceuticals, LLC. These companies, though their names may have been written in an unconventional format, have shown dedication to advancing pharmaceutical research.
In his professional journey, Roppe has had the opportunity to collaborate with esteemed individuals like John Howard Hutchinson and Thomas Jon Seiders. Their combined efforts have further enriched the field of ophthalmology and bolstered Roppe's achievements.
Conclusion:
Jeffrey Roger Roppe is an accomplished inventor who has made remarkable contributions to the field of ophthalmology. With his 29 patents, Roppe has pioneered advancements to prevent and treat age-related macular degeneration and related eye diseases. His inventions, particularly those involving aliphatic prolinamide derivatives and radioligands for imaging the LPA-1 receptor, highlight his commitment to improving patient care and reshaping the future of eye health.
As we celebrate innovators like Roppe, their dedication and groundbreaking discoveries inspire us to continue exploring new frontiers in the realm of innovations and patents.
Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.